Teva Settles Inhaler-Patents Case Over Deva’s ProAir Copy (1)

April 11, 2025, 8:11 PM UTCUpdated: April 11, 2025, 9:38 PM UTC

Teva Pharmaceutical Industries Ltd. agreed to end a patent-infringement lawsuit that sought to block a copy of its ProAir HFA inhaler proposed by Deva Holding AS, one month after the Federal Circuit ordered Teva to remove certain patents from an FDA registry.

The deal leaves the door open for either side to renew its allegations, according to a proposed consent dismissal order filed Thursday in the US District Court for the District of New Jersey. Magistrate Judge Michael A. Hammer on Friday issued a text order canceling a status teleconference slated for April 14.

  • Teva reached “a confidential settlement” with ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.